BioCentury
ARTICLE | Financial News

Immunomedics planning follow-on

May 2, 2014 12:10 AM UTC

Immunomedics Inc. (NASDAQ:IMMU) proposed a follow-on late Thursday underwritten by Wells Fargo Securities and Jefferies. Immunomedics' most advanced internal program, Yttrium-90-clivatuzumab tetraxetan (formerly IMMU-107), is in the Phase III PANCRIT-1 trial to treat metastatic pancreatic cancer, with top-line data expected as early as 1Q16. The product is an yttrium-90 radiolabeled humanized mAb against mucin 1 ( MUC1; CD227).

The company's most advanced partnered program, epratuzumab ( IMMU-103), is in the Phase III EMBODY 1 and 2 trials to treat moderate to severe systemic lupus erythematosus (SLE), with data expected in 1Q15. UCB Group (Euronext:UCB) has rights to the humanized mAb targeting CD22 for autoimmune indications. ...